etoposide has been researched along with thalidomide in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (49.28) | 29.6817 |
| 2010's | 29 (42.03) | 24.3611 |
| 2020's | 6 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Butch, AW; Flick, JT; Pappas, AA; Yeh, YA | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Hawighorst, H; Hillengass, J; Ho, AD; Max, R; Moehler, TM; Neben, K; van Kaick, G | 1 |
| Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fink, L; Gopal, AV; Morris, C; Siegel, E; Toor, A; Tricot, G; Zangari, M | 1 |
| D'Orazio, AI | 1 |
| Benner, A; Egerer, G; Goldschmidt, H; Ho, AD; Krasniqi, F; Moehler, TM; Neben, K | 1 |
| Lichtman, SM; Skirvin, JA | 1 |
| Anaissie, E; Badros, A; Barlogie, B; Desikan, R; Fassas, A; Fink, L; Mehta, P; Morris, C; Saghafifar, F; Siegel, E; Toor, A; Tricot, G; Whitfield, D; Zangari, M | 1 |
| Drach, J; Kaufmann, H; Nösslinger, T; Raderer, M; Urbauer, E | 1 |
| Badros, A; Barlogie, B; Morris, C; Tricot, G; Zangari, M | 1 |
| Alinari, L; Baccarani, M; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Barlogie, B; Eddleman, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Talamo, G; Thertulien, R; Tricot, G; Van Rhee, F; Zangari, M | 1 |
| Mehta, J; Pichardo, D; Rosen, S; Singhal, S | 1 |
| Delorme, S; Düber, C; Goldschmidt, H; Heiss, J; Hillengass, J; Kauczor, HU; Moehler, T; Neben, K; Nosas, S; Wasser, K | 1 |
| Hussein, MA | 1 |
| Glasmacher, A; von Lilienfeld-Toal, M | 1 |
| Enschede, SH; Gregory, SA; Larson, ML | 1 |
| Kunihiko, M; Mariko, Y; Shinichiro, O; Yasuo, I; Yusuke, T; Yutaka, H | 1 |
| Akpek, G; Badros, A; Fenton, R; Goloubeva, O; Harris, C; Meisenberg, B; Rapoport, AP; Ruehle, K; Westphal, S | 1 |
| Alsayed, Y; Anaissie, E; Barlogie, B; Bolejack, V; Crowley, J; Epstein, J; Hollmig, K; Mohiuddin, A; Pineda-Roman, M; Shaughnessy, JD; Tricot, G; van Rhee, F; Woods, G; Zangari, M | 1 |
| Batchelor, TT; Black, PM; Bradshaw, J; Chen-Plotkin, AS; Doherty, L; Drappatz, J; Folkman, J; Gigas, DC; Kesari, S; Kieran, M; Kracher, J; Laforme, A; Levy, B; Muzikansky, A; O'Neill, A; Ramakrishna, N; Schiff, D; Weiss, SE; Wen, PY | 1 |
| Abidi, MH; Ibrahim, RB; Maria, D; Peres, E; Tove, I | 1 |
| Heath, J; Kanwar, VS; Krasner, CN; Pearce, JM | 1 |
| Buchler, T; Ellis, P; Hackshaw, A; James, L; Lee, SM; Snee, M | 1 |
| Chen, YB; Fu, WJ; Hou, J; Wang, DX; Xi, H; Yuan, ZG | 1 |
| Davies, FE; Dines, S; Ethell, ME; Jenner, MW; Morgan, GJ; Potter, MN; Saso, RM; Shaw, BE; Srikanth, M; Wu, P | 1 |
| Claxton, D; Fink, LM; Ibrahim, S; Talamo, GP; Tricot, GJ; Zangari, M | 1 |
| Bernard, C; Grushka, JR; Laberge, JM; Mueller, C; Nguyen, VH; Puligandla, PS; Roessingh, Ade B; Ryckman, J; St Vil, D; Walton, JM | 1 |
| Alousi, A; Anderlini, P; Andersson, B; Champlin, R; de Lima, M; Giralt, S; Hosing, C; Jones, R; Kebriaei, P; Khouri, I; Körbling, M; McMannis, J; Nieto, Y; Popat, U; Qazilbash, M; Saliba, R; Shpall, E; Thandi, R; Thomas, S; Wang, M; Weber, D | 1 |
| Gafter-Gvili, A; Magen-Nativ, H; Raanani, P; Ram, R; Shpilberg, O; Yeshurun, M | 1 |
| Musallam, KM; Taher, AT | 1 |
| García-Sanz, R; González-López, TJ; Graciani, IF; Hermida, G; San Miguel, JF; Vázquez, L | 1 |
| Mateos, MV; San-Miguel, JF | 1 |
| Byrne, GE; Coleman, F; Escalón, MP; Hosein, PJ; Lossos, IS; Morgensztern, D; Rosenblatt, JD; Walker, GR | 1 |
| Cheung, K; Coleman, M; Elstrom, R; Faye, A; Furman, RR; Hajjar, KA; Lachs, M; Leonard, JP; Martin, P; Ruan, J | 1 |
| Kivivuori, SM; Lönnqvist, T; Riikonen, P; Saarinen-Pihkala, UM; Valanne, L | 1 |
| Berthou, C; Eveillard, JR; Guillerm, G; Ianotto, JC; Tempescul, A | 1 |
| Kivivuori, SM; Nygaard, R | 1 |
| Brown, NJ; Jitlal, M; Lee, SM; Tin, AW; Woll, PJ; Young, RJ | 1 |
| Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L | 1 |
| Beck, R; Ellis, PM; Fandi, A; Jungnelius, U; Shepherd, FA; Zhang, J | 1 |
| Chen, CI; Cheng, L; Gerrie, AS; Jiang, H; Kukreti, V; Mikhael, JR; Panzarella, T; Reece, D; Stewart, KA; Trieu, Y; Trudel, S | 1 |
| Chen, CI; Chu, CM; Cserti-Gazdewich, C; Jiang, H; Jimenez-Zepeda, VH; Kukreti, V; Masih-Khan, E; Rabea, A; Reece, DE; Tiedemann, R; Trudel, S; Tsang, R | 1 |
| Cavenagh, J; Ingram, W; Quinn, J; Smith, D; Stevens, J; Yong, K | 1 |
| Allen, JC; Bendel, AE; Campigotto, F; Chi, SN; Chordas, CA; Comito, MA; Goldman, S; Hubbs, SM; Isakoff, MS; Khatib, ZA; Kieran, MW; Kondrat, L; Manley, PE; Neuberg, DS; Pan, WJ; Pietrantonio, JB; Robison, NJ; Rubin, JB; Turner, CD; Werger, AM; Zimmerman, MA | 1 |
| Garami, M; Hauser, P; Pócza, T; Schuler, D; Vancsó, I | 1 |
| Beaven, AW; Bejot, C; Bhattacharyya, P; Carini, C; Chow, KF; Donato, ML; Feldman, T; Gadaleta, G; Goy, A; Kdiry, S; Mato, AR; Pecora, AL; Protomastro, EA; Rowley, SD; Smith, J; Stives, S; Timberg, M; Valentinetti, M; Yang, X; Yannotti, KM | 1 |
| Arola, M; Clausen, N; Harila-Saari, A; Holm, S; Kivivuori, SM; Lähteenmäki, P; Lannering, B; Lönnqvist, T; Porkholm, M; Riikonen, P; Saarinen-Pihkala, UM; Schomerus, E; Sehested, A; Thomassen, H; Thorarinsdottir, HK; Valanne, L; Wojcik, D | 1 |
| Magen, H; Muchtar, E; Oniashvili, N; Raanani, P; Ram, R; Shpilberg, O; Yeshurun, M | 1 |
| Argnani, L; Maglie, R; Pellegrini, C; Pileri, S; Zinzani, PL | 1 |
| Alsina, M; Baz, RC; Fulp, W; Griffin, PT; Ho, VQ; Nishihori, T; Shain, KH | 1 |
| Caballero, D; Canales, M; Dlouhy, I; González-Barca, E; López-Guillermo, A; Martín, A; Montes-Moreno, S; Ocio, EM; Redondo, AM; Salar, A | 1 |
| Yang, YZ | 1 |
| Agarwala, S; Bakhshi, S; Batra, A; Dhawan, D; Gupta, YK; Pramanik, R; Thulkar, S; Vishnubhatla, S | 1 |
| Baker, L; Holder, K; Kanellopoulos, A; Kaparou, M; Kishore, B; Lovell, R; Nikolousis, E; Paneesha, S; Randall, K; Ryan, L; Suhr, J; Xenou, E | 1 |
| Buadi, FK; Dingli, D; Dispenzieri, A; Fonder, AL; Gertz, MA; Go, RS; Gonsalves, WI; Hayman, SR; Hobbs, M; Hwa, YL; Kapoor, P; Kourelis, T; Kumar, SK; Kyle, RA; Lacy, MQ; Lakshman, A; Leung, N; Lin, Y; Lust, JA; Rajkumar, SV; Russell, SJ; Singh, PP; Warsame, R; Zeldenrust, SR | 1 |
| Minkov, M | 1 |
| Ashizuka, S; Baba, Y; Harada, A; Hiramatsu, T; Kaji, S; Kanamori, D; Miyaguni, K; Ohki, T; Sugihara, T; Uchida, G; Yoshizawa, J | 1 |
| Barlogie, B; Mouhieddine, TH; Teruya-Feldstein, J | 1 |
| Ainley, L; Chavda, SJ; Cheesman, S; Counsell, N; Horder, J; Kyriakou, C; Lee, L; Mehta, A; Newrick, F; Papanikolaou, X; Popat, R; Rabin, N; Sive, J; Wechalekar, A; Yong, K | 1 |
| Alderuccio, JP; Alencar, AJ; Iyer, SG; Lossos, IS; Reis, IM; Rosenblatt, JD; Saul, EE | 1 |
| Cai, Q; Song, W; Sun, X; Wang, L; Wang, Y; Xue, H; Zhang, H; Zhang, L; Zhang, M; Zou, L | 1 |
| Andoh, S; Hagiwara, S; Hirai, R; Itoi, S; Komuro, M; Mitsui, Y; Miwa, A; Nakamura, M; Sekine, R; Takeshita, M; Tanimura, A; Togano, T | 1 |
| Hou, SL; Li, L; Lian, K; Zhang, QH | 1 |
8 review(s) available for etoposide and thalidomide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Complementary Therapies; Cytochrome P-450 Enzyme System; Dacarbazine; Etoposide; Humans; Idarubicin; Neoplasms; Tamoxifen; Temozolomide; Thalidomide; Topotecan | 2002 |
Recent developments and future directions in the treatment of multiple myeloma.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Transplantation; Clinical Trials as Topic; Cysteine Endopeptidases; Diphosphonates; Doxorubicin; Erythropoietin; Etoposide; Forecasting; Humans; Interferons; Multienzyme Complexes; Multiple Myeloma; Organometallic Compounds; Organophosphorus Compounds; Oxides; Peripheral Blood Stem Cell Transplantation; Proteasome Endopeptidase Complex; Thalidomide; Tissue Extracts | 2003 |
The current status of thalidomide in the management of multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Pyrazines; Retrospective Studies; Thalidomide; Tumor Necrosis Factor-alpha | 2005 |
HIV-related lymphoma treated with maintenance thalidomide.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Axilla; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphatic Irradiation; Lymphoma, AIDS-Related; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Thalidomide; Vincristine | 2005 |
Spindle epithelial tumor with thymus-like elements of the thyroid: a multi-institutional case series and review of the literature.
Topics: Abscess; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma; Celecoxib; Child; Child, Preschool; Choristoma; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Deoxycytidine; Diagnostic Errors; Doxorubicin; Etoposide; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Pyrazoles; Radiography; Sulfonamides; Teratoma; Thalidomide; Thymus Gland; Thyroid Neoplasms; Thyroidectomy | 2009 |
How to treat a newly diagnosed young patient with multiple myeloma.
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Chromosome Aberrations; Combined Modality Therapy; Disease Management; Doxorubicin; Endpoint Determination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Middle Aged; Molecular Diagnostic Techniques; Multicenter Studies as Topic; Multiple Myeloma; Myeloablative Agonists; Pyrazines; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide; Transplantation Conditioning | 2009 |
An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy.
Topics: Antineoplastic Agents; Central Nervous System; Child; Clinical Trials as Topic; Drug Therapy, Combination; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Prednisolone; Thalidomide; Vinblastine | 2018 |
20 trial(s) available for etoposide and thalidomide
| Article | Year |
|---|---|
[Functional magnetic resonance tomography in the diagnosis and therapy monitoring in multiple myeloma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cyclophosphamide; Dexamethasone; Drug Monitoring; Etoposide; Humans; Ilium; Immunohistochemistry; Lumbar Vertebrae; Magnetic Resonance Imaging; Microcirculation; Multiple Myeloma; Thalidomide | 2000 |
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Factors; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Risk; Risk Factors; Thalidomide; Venous Thrombosis; Vincristine | 2001 |
Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.
Topics: Activated Protein C Resistance; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Coagulation Tests; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Factor V; Female; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Life Tables; Male; Middle Aged; Multiple Myeloma; Risk; Thalidomide; Thrombophilia; Venous Thrombosis; Vincristine | 2002 |
Thromboembolic events during treatment with thalidomide.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Lymphoma, Mantle-Cell; Multiple Myeloma; Prednisone; Rituximab; Thalidomide; Thromboembolism; Vincristine | 2002 |
[Dynamic MRI of the bone marrow for monitoring multiple myeloma during treatment with thalidomide as monotherapy or in combination with CED chemotherapy].
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Marrow; Cyclophosphamide; Data Interpretation, Statistical; Dexamethasone; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Multiple Myeloma; Prospective Studies; Remission Induction; Thalidomide; Time Factors; Treatment Outcome | 2004 |
Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Humans; Male; Middle Aged; Multiple Myeloma; Proteasome Inhibitors; Pyrazines; Remission Induction; Stem Cell Transplantation; Thalidomide; Treatment Outcome | 2006 |
High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blood Proteins; Bone Marrow; Boronic Acids; Bortezomib; Cisplatin; Creatinine; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Immunoglobulin Light Chains; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2007 |
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Celecoxib; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Pyrazoles; Sulfonamides; Thalidomide | 2007 |
Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Disease Progression; Etoposide; Female; Humans; Lung Neoplasms; Male; Prognosis; Survival Rate; Thalidomide; Treatment Outcome | 2008 |
[Bortezomib-based combination therapy for relapsed or refractory multiple myeloma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Constipation; Cyclophosphamide; Dexamethasone; Dizziness; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Pyrazines; Thalidomide; Treatment Outcome | 2008 |
High rate and prolonged duration of complete remissions induced by rituximab, methotrexate, doxorubicin, cyclophosphamide, vincristine, ifosfamide, etoposide, cytarabine, and thalidomide (R-MACLO-IVAM-T), a modification of the National Cancer Institute 89
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Ifosfamide; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Remission Induction; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2010 |
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Etoposide; Female; Humans; Lymphoma, Mantle-Cell; Male; Middle Aged; Neovascularization, Pathologic; Prednisone; Procarbazine; Quality of Life; Recurrence; Rituximab; Thalidomide; Treatment Outcome | 2010 |
A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Small Cell Lung Carcinoma; Survival Rate; Thalidomide | 2013 |
A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Etoposide; Female; Fenofibrate; Follow-Up Studies; Humans; Infant; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Prognosis; Prospective Studies; Pyrazoles; Sulfonamides; Survival Rate; Thalidomide; Young Adult | 2014 |
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Ifosfamide; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Prognosis; Recurrence; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2014 |
Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cisplatin; Cytarabine; Dose-Response Relationship, Drug; Etoposide; Female; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Treatment Outcome; Young Adult | 2016 |
[Clinical Efficacy Comparison between CHOPE Regimen alone and It Combined with Thalidomide for Relapsed and Refractory Non-Hodgkin's Lymphoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Lactate Dehydrogenases; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Prednisone; Survival Rate; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A; Vincristine | 2016 |
Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Topics: Administration, Metronomic; Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Child; Child, Preschool; Cyclophosphamide; Disease Progression; Disease-Free Survival; Double-Blind Method; Etoposide; Female; Follow-Up Studies; Humans; Male; Neoplasms; Response Elements; Retreatment; Sarcoma, Ewing; Survival Rate; Thalidomide; Time Factors | 2017 |
R-MACLO-IVAM regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma - Long term follow up results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytarabine; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Kaplan-Meier Estimate; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Methotrexate; Middle Aged; Progression-Free Survival; Prospective Studies; Remission Induction; Rituximab; Thalidomide; Vincristine; Young Adult | 2021 |
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Humans; Lymphoma, T-Cell, Peripheral; Neutropenia; Prednisone; Thalidomide; Treatment Outcome | 2022 |
41 other study(ies) available for etoposide and thalidomide
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
A case of aggressive multiple myeloma with cleaved, multilobated, and monocytoid nuclei, and no serum monoclonal gammopathy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Cells; Cell Cycle; Cisplatin; Cyclophosphamide; Dexamethasone; Etoposide; Flow Cytometry; Humans; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Leukemia, Plasma Cell; Male; Multiple Myeloma; Neoplasms, Second Primary; Prognosis; Thalidomide | 2000 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunosuppressive Agents; Immunotoxins; Lectins; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Thalidomide; Vinblastine | 2001 |
Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Multiple Myeloma; Prognosis; Recurrence; Remission Induction; Salvage Therapy; Survival Rate; Thalidomide | 2001 |
Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cell Division; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Neoplastic Stem Cells; Peripheral Blood Stem Cell Transplantation; Thalidomide; Vincristine | 2002 |
Waldenstrom's macroglobulinemia: is there a place and time for a cease-fire?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Case Management; Chlorambucil; Cladribine; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Immunoglobulin M; Male; Middle Aged; Mitoxantrone; Plasmapheresis; Prednisone; Rituximab; Severity of Illness Index; Thalidomide; Vidarabine; Vinblastine; Vincristine; Vinorelbine; Waldenstrom Macroglobulinemia | 2003 |
Thalidomide and deep vein thrombosis in multiple myeloma: risk factors and effect on survival.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Humans; Multiple Myeloma; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Venous Thrombosis; Vincristine | 2003 |
Thalidomide: new indication. A last resort in myeloma.
Topics: Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Approval; Drug Therapy, Combination; Etoposide; Female; France; Humans; Interferon alpha-2; Interferon-alpha; Male; Multiple Myeloma; Recombinant Proteins; Thalidomide | 2003 |
Salvage therapy options for myeloma patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Doxorubicin; Etoposide; Glucocorticoids; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Plasmapheresis; Radiotherapy, Adjuvant; Salvage Therapy; Spine; Thalidomide | 2004 |
Thalidomide for the treatment of leptomeningeal multiple myeloma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fatal Outcome; Female; Humans; Immunoglobulin G; Melphalan; Meningeal Neoplasms; Middle Aged; Multiple Myeloma; Nitrosourea Compounds; Prednisolone; Prednisone; Thalidomide; Vindesine | 2006 |
Thalidomide for the treatment of histiocytic sarcoma after hematopoietic stem cell transplant.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Histiocytes; Humans; Middle Aged; Prednisone; Retroperitoneal Neoplasms; Sarcoma; Thalidomide; Vincristine | 2007 |
Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bleomycin; Carcinoma, Small Cell; Celecoxib; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Etoposide; Female; Humans; Imatinib Mesylate; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Piperazines; Pyrazoles; Pyrimidines; Sulfonamides; Thalidomide; Vinblastine | 2008 |
Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Recurrence; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous | 2008 |
Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
Topics: Activated Protein C Resistance; Angiogenesis Inhibitors; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dexamethasone; Doxorubicin; Etoposide; Factor V; Follow-Up Studies; Humans; Hyperhomocysteinemia; Multiple Myeloma; Prednisone; Pulmonary Embolism; Retrospective Studies; Thalidomide; Thrombophilia; Venous Thrombosis | 2009 |
Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Bone Marrow; Combined Modality Therapy; Cyclams; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Ifosfamide; Lenalidomide; Leukapheresis; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Retrospective Studies; Risk Factors; Thalidomide; Transplantation, Autologous; Treatment Failure; Vincristine | 2009 |
Total therapy-based treatment for multiple myeloma--a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2010 |
Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Etoposide; Humans; Incidence; Lung Neoplasms; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Thalidomide; Thromboembolism | 2009 |
The combination of thalidomide, cyclophosphamide and dexamethasone is potentially useful in highly resistant Hodgkin's lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dacarbazine; Deoxycytidine; Dexamethasone; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hodgkin Disease; Humans; Male; Mechlorethamine; Melphalan; Organoplatinum Compounds; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prednisone; Procarbazine; Remission Induction; Rituximab; Salvage Therapy; Thalidomide; Topotecan; Transplantation, Autologous; Vidarabine; Vinblastine; Vincristine | 2010 |
Antiangiogenic combination therapy after local radiotherapy with topotecan radiosensitizer improved quality of life for children with inoperable brainstem gliomas.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Celecoxib; Child; Child, Preschool; Disease Progression; Etoposide; Glioma; Humans; Pilot Projects; Pyrazoles; Quality of Life; Radiation-Sensitizing Agents; Sulfonamides; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome | 2011 |
ESHAP chemotherapy regimen associated to lenalidomide induces complete isotopic remission in Hodgkin's lymphoma relapsing after autologous stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Prednisone; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2011 |
Treatment for recurrent medulloblastoma with intrathecal liposomal cytarabine and systemic metronomic combination therapy.
Topics: Administration, Metronomic; Adolescent; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cerebellar Neoplasms; Cytarabine; Etoposide; Humans; Injections, Spinal; Liposomes; Male; Medulloblastoma; Neoplasm Recurrence, Local; Neutropenia; Pyrazoles; Sulfonamides; Thalidomide; Treatment Outcome | 2012 |
Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Deoxycytidine; Etoposide; Female; Fibroblast Growth Factor 2; Gemcitabine; Humans; Intercellular Adhesion Molecule-1; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Neovascularization, Pathologic; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Survival Analysis; Thalidomide; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality Therapy; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Melphalan; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Thalidomide; Transplantation, Autologous | 2012 |
D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Central nervous system involvement with multiple myeloma: long term survival can be achieved with radiation, intrathecal chemotherapy, and immunomodulatory agents.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Central Nervous System; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Injections, Spinal; Kaplan-Meier Estimate; Lenalidomide; Male; Meninges; Middle Aged; Multiple Myeloma; Orbit; Proportional Hazards Models; Pyrazines; Radiotherapy, Adjuvant; Retrospective Studies; Salvage Therapy; Spine; Thalidomide; Transplantation, Autologous; Treatment Outcome; Vincristine | 2013 |
Myeloma presenting during pregnancy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cesarean Section; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Contraindications; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Fatal Outcome; Female; Hematopoietic Stem Cell Transplantation; Humans; Hypercalcemia; Idarubicin; Infant, Newborn; Lenalidomide; Male; Melphalan; Methylprednisolone; Multiple Myeloma; Myeloma Proteins; Osteolysis; Plasmacytoma; Postpartum Period; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Outcome; Pyrazines; Remission Induction; Spinal Cord Compression; Thalidomide; Thoracic Vertebrae; Transplantation, Autologous | 2014 |
[Antiangiogenic treatment of pediatric CNS tumors in Hungary with the Kieran schedule].
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Bone Marrow; Brain Neoplasms; Brain Stem Neoplasms; Carcinoma; Celecoxib; Cerebellar Neoplasms; Child; Child, Preschool; Choroid Plexus Neoplasms; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Ependymoma; Etoposide; Female; Humans; Hungary; Ischemic Attack, Transient; Male; Medulloblastoma; Neuroectodermal Tumors, Primitive; Optic Nerve Glioma; Pyrazoles; Quality of Life; Retrospective Studies; Sulfonamides; Thalidomide; Treatment Outcome | 2013 |
Radiation therapy and concurrent topotecan followed by maintenance triple anti-angiogenic therapy with thalidomide, etoposide, and celecoxib for pediatric diffuse intrinsic pontine glioma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Case-Control Studies; Celecoxib; Chemoradiotherapy; Chemotherapy, Adjuvant; Child; Child, Preschool; Etoposide; Female; Follow-Up Studies; Glioma; Humans; Infant; Male; Neoplasm Grading; Prognosis; Pyrazoles; Quality of Life; Remission Induction; Sulfonamides; Survival Rate; Thalidomide; Topotecan | 2014 |
First line and salvage therapy with total therapy 3-based treatment for multiple myeloma- an extended single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Retrospective Studies; Salvage Therapy; Survival Rate; Thalidomide | 2014 |
Impressive response to pegylated liposomal doxorubicin after allogeneic transplantation in a multi-relapsed Hodgkin's lymphoma.
Topics: Allografts; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Carmustine; Combined Modality Therapy; Cytarabine; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Liposomes; Male; Melphalan; Polyethylene Glycols; Recurrence; Remission Induction; Salvage Therapy; Thalidomide; Transplantation, Autologous; Young Adult | 2016 |
A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Salvage Therapy; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT-PACE in myeloma patients relapsing early after autologous transplant.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Recurrence; Retreatment; Survival Analysis; Thalidomide; Transplantation Chimera; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome | 2017 |
Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubicin; Etoposide; Humans; Middle Aged; Multiple Myeloma; Salvage Therapy; Stem Cell Transplantation; Survival Analysis; Thalidomide; Treatment Outcome; Vincristine | 2018 |
Thalidomide potentiates etoposide-induced apoptosis in murine neuroblastoma through suppression of NF-κB activation.
Topics: Animals; Apoptosis; Cell Line, Tumor; DNA, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Mice; Neoplasms, Experimental; Neuroblastoma; NF-kappa B; Phosphorylation; Signal Transduction; Thalidomide; Up-Regulation | 2018 |
Hemophagocytic relapsed intramedullary plasmacytoma.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Bortezomib; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Magnetic Resonance Imaging; Melphalan; Neoplasm Recurrence, Local; Oligopeptides; Plasmacytoma; Positron Emission Tomography Computed Tomography; Pubic Bone; Rare Diseases; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2020 |
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Dexamethasone; Doxorubicin; Etoposide; Female; Humans; Male; Methylprednisolone; Middle Aged; Multiple Myeloma; Progression-Free Survival; Salvage Therapy; Stem Cell Transplantation; Thalidomide; Transplantation, Autologous; Young Adult | 2021 |
Bortezomib-thalidomide-dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide as a Salvage and Bridging Regimen before Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cisplatin; Cyclophosphamide; Dexamethasone; Doxorubicin; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Multiple Myeloma; Retrospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2022 |
Study of a metronomic-chemotherapy regimen comprising prednisone, etoposide and procarbazine combined with thalidomide±Rituxan for relapsed refractory B-cell lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Lymphoma, B-Cell; Neoplasm Recurrence, Local; Prednisone; Procarbazine; Rituximab; Thalidomide; Treatment Outcome | 2023 |